Clinical trial
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating…
NCT00101127 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00101127 |
|---|---|
| Title | Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma |
| Official title | A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, pegfilgrastim, docetaxel, gemcitabine hydrochloride |
| Start date | Dec 1, 2003 |
| Primary completion | Jul 1, 2006 |
| First posted | Jan 10, 2005 |
| Last update posted | Feb 14, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: